Development of an Intelligent Diagnosis Model for Neoadjuvant Therapeutic Tumor Regression Grading in Patients with Pancreatic Cancer by Deep Learning of Patho-radiomics

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000038576

Enrollment

Unknown

Registered

2020-09-24

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer

Interventions

Gold Standard:Pathological rasults

Index test:Radiomics scores

Eligibility

Sex/Gender

All

Age

30 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Pancreatic cancer patient without any preoperative radiation, chemotherapy or other treatment; 2) standard contrast-enhanced High resolution CT and/or 3.0T MRI scan of the pancreas were performed within 15 days before surgery; 3) surgical resection of pancreatic cancer; 4) pathological standard samples were taken and large histopathological sections were prepared; 5) preoperative ca19-9 and CEA data were available.

Exclusion criteria

Exclusion criteria: 1) treatment of any type (radiotherapy, chemotherapy, or chemoradiotherapy) before the imaging studies were performed, 2) not evaluated by standard contrast-enhanced High resolution CT and/or 3.0T MRI within 15 days before surgery; 3) no history of surgical treatment; 4) no pathological standard samples were taken and large histopathological sections were prepared; 5) no preoperative ca19-9 and CEA data were available.

Design outcomes

Primary

Measure	Time frame
Radiomics score;	—

Countries

China

Contacts

Public ContactBianyun

bianyun2012@foxmail.com+86 13816357024

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026